Innovative treatment strategies for patients with rheumatoid arthritis
- PMID: 18388520
- DOI: 10.1097/BOR.0b013e3282fa13db
Innovative treatment strategies for patients with rheumatoid arthritis
Abstract
Purpose of review: The present review provides an update on novel treatment strategies striving for remission in patients with recent onset of rheumatoid arthritis.
Recent findings: As early treatment is crucial to achieve optimal results, identifying patients with rheumatoid arthritis early is imperative to achieve clinical remission. Patients with early arthritis who will progress to rheumatoid arthritis can be identified, and treating these patients can postpone the diagnosis of rheumatoid arthritis and retard the progression of structural damage. The best way to achieve remission is by adjusting treatments at regular intervals using predetermined response criteria. Specific treatments to rapidly induce remission include disease modifying antirheumatic drugs combinations, especially combined with glucocorticoids or tumor necrosis factor antagonists. The prediction of joint damage progression, or the response to specific drugs is not yet accurately possible. The early institution of tumor necrosis factor antagonists followed by discontinuation leads to sustained clinical benefit.
Summary: Early treatment of patients with rheumatoid arthritis with strategies aiming at remission results in the best outcomes. Until the prediction of a severe disease course and treatment response becomes possible, a promising strategy would be to rapidly induce remission using an effective combination of drugs followed by tapering and discontinuation. Tumor necrosis factor antagonists have proven to be highly effective in this approach.
Similar articles
-
Biologic therapy for early rheumatoid arthritis: the latest evidence.Curr Opin Rheumatol. 2008 May;20(3):314-9. doi: 10.1097/BOR.0b013e3282f5fcf6. Curr Opin Rheumatol. 2008. PMID: 18388524 Review.
-
Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes.Nat Clin Pract Rheumatol. 2006 Nov;2(11):594-601. doi: 10.1038/ncprheum0340. Nat Clin Pract Rheumatol. 2006. PMID: 17075598 Review.
-
Early rheumatoid arthritis.Curr Opin Rheumatol. 2007 May;19(3):278-83. doi: 10.1097/BOR.0b013e32805e87bf. Curr Opin Rheumatol. 2007. PMID: 17414956 Review.
-
Optimizing treatment with biologics.J Rheumatol Suppl. 2007 Nov;80:16-24. J Rheumatol Suppl. 2007. PMID: 17985419 Review.
-
The BeSt story: on strategy trials in rheumatoid arthritis.Curr Opin Rheumatol. 2009 May;21(3):291-8. doi: 10.1097/BOR.0b013e32832a2f1c. Curr Opin Rheumatol. 2009. PMID: 19318946 Review.
Cited by
-
Flavonoid quercetin-methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis.Inflammopharmacology. 2018 Oct;26(5):1219-1232. doi: 10.1007/s10787-018-0464-2. Epub 2018 Apr 3. Inflammopharmacology. 2018. PMID: 29616452
-
The regulatory role of immunosuppressants on immune abnormalities in acute pancreatitis.Biomed Rep. 2014 Mar;2(2):193-198. doi: 10.3892/br.2013.208. Epub 2013 Nov 29. Biomed Rep. 2014. PMID: 24649095 Free PMC article.
-
Biologic therapy for inflammatory bowel disease comes of age.Curr Gastroenterol Rep. 2008 Dec;10(6):565-6. Curr Gastroenterol Rep. 2008. PMID: 19006611 No abstract available.
-
Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.Arthritis Res Ther. 2016 Mar 8;18:60. doi: 10.1186/s13075-016-0962-9. Arthritis Res Ther. 2016. PMID: 26956382 Free PMC article.
-
Rheumatoid arthritis: what has changed?Skeletal Radiol. 2009 Feb;38(2):109-12. doi: 10.1007/s00256-008-0579-4. Skeletal Radiol. 2009. PMID: 18773202 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials